PMID- 31482479
OWN - NLM
STAT- MEDLINE
DCOM- 20200821
LR  - 20200821
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 20
IP  - 10
DP  - 2019 Sep 4
TI  - Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
PG  - 79
LID - 10.1007/s11864-019-0675-9 [doi]
AB  - There has been rapid progress in the use of targeted therapies for ALK-positive 
      which has led to improve dramatically PFS and OS in the metastatic ALK-rearranged 
      NSCLC patients. There are several molecules now available (crizotinib, ceritinib, 
      brigatinib, alectinib, and lorlatinib) and others in development. Such an 
      improvement in treatment efficacy has even more highlighted the importance of an 
      adequate identification of ALK alterations. Efficient and easily accessible 
      testing tools are required to identify eligible patients in a timely fashion. 
      Different methods for detecting ALK+ NSCLC patients are now available, with 
      fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) 
      currently representing validated diagnostic techniques for the initial assessment 
      of ALK status. Furthermore the widespread use of next-generation sequencing to 
      detect other possible different activating mutations has allowed to identify 
      individual ALK fusion variants. Several more expensive and time-consuming methods 
      are also available nowadays which have the advantage to detect even rarer 
      uncommon ALK fusion variants and mutations in tumour or blood samples. A review 
      of the evolving testing-treatment landscape is needed to highlight the importance 
      of properly diagnosing and treating this group of patients.
FAU - Friedlaender, Alex
AU  - Friedlaender A
AD  - Oncology Department, Geneva University Hospital (CH), Rue Gabrielle-Perret-Gentil 
      4, 1205, Geneve, Switzerland.
FAU - Banna, Giuseppe
AU  - Banna G
AD  - Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.
FAU - Patel, Sandip
AU  - Patel S
AD  - Sandip Pravin Patel, UC San Diego Moores Cancer Center, 3855 Health Sciences Dr, 
      La Jolla, CA, 92037, USA.
FAU - Addeo, Alfredo
AU  - Addeo A
AD  - Oncology Department, Geneva University Hospital (CH), Rue Gabrielle-Perret-Gentil 
      4, 1205, Geneve, Switzerland. alfredo.addeo@hcuge.ch.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190904
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/antagonists & inhibitors/*genetics
MH  - Biomarkers, Tumor
MH  - Carcinoma, Non-Small-Cell Lung/*diagnosis/*etiology/*therapy
MH  - *Chromosome Aberrations
MH  - Disease Management
MH  - Humans
MH  - Liquid Biopsy/methods
MH  - Lung Neoplasms/*diagnosis/*etiology/*therapy
MH  - Molecular Diagnostic Techniques
MH  - Molecular Targeted Therapy/methods
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
OTO - NOTNLM
OT  - ALK aberration
OT  - NSCLC
OT  - Testing
EDAT- 2019/09/05 06:00
MHDA- 2020/08/22 06:00
CRDT- 2019/09/05 06:00
PHST- 2019/09/05 06:00 [entrez]
PHST- 2019/09/05 06:00 [pubmed]
PHST- 2020/08/22 06:00 [medline]
AID - 10.1007/s11864-019-0675-9 [pii]
AID - 10.1007/s11864-019-0675-9 [doi]
PST - epublish
SO  - Curr Treat Options Oncol. 2019 Sep 4;20(10):79. doi: 10.1007/s11864-019-0675-9.